Pfizer (PFE) has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug, Bloomberg’s Jef Feeley reports, citing people familiar with the matter. The agreements cover cases in state courts across the U.S. but don’t completely resolve the company’s exposure to Zantac claims, according to the people. The deal is likely to reassure investors, who have seen other Zantac makers, including GSK (GSK) and Sanofi (SNY), sign settlements.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer (NYSE:PFE) Halts Gene Therapy Trial After Patient Death
- Pfizer appoints Andrew Baum as Chief Strategy and Innovation Officer
- Moderna price target raised to $155 from $125 at Jefferies
- Pfizer (PFE) Announces Q2 Dividend: Read On for Important Dates
- Genmab reports Q1 revenue increased 46% vs. last year